LumiraDx Limited (NASDAQ:LMDX) Q4 2022 Earnings Call Transcript

Andrew Cooper: Is there any likelihood of that becoming an Ultra product over time? Or it’s kind of mechanically not something that’s necessarily feasible?

Dorian LeBlanc: It is something that’s feasible and I think we were ensuring that we met the timelines to have the product in the market for the upcoming flu season versus continued development on an Ultra version?

Ron Zwanziger: But all our developments are going into the Ultra program. This was expedient to make sure we got it into the U.S. quickly. But in general, all our tests coming through are switching to the Ultra platform.

Andrew Cooper: Okay, great. That makes sense. I will stop there. Thanks for the time.

Operator: And I would now like to hand the call back to Ron for closing remarks.

Ron Zwanziger: Well, over the past couple of quarters, we focused on reshaping our business priorities, assets and organization structure to accelerate the near term delivery. Having done this, we’ve been able to now reinvest and bring momentum to our highest value programs. We continue to advance our product and pipeline strategy for transforming the (ph) point of care diagnostic markets and we look forward to updating you on our progress and appreciate your continued support. Thanks very much.

Operator: And ladies and gentlemen, this concludes today’s conference call. Thank you for participating. You may now disconnect.